Welcome to our dedicated page for Mirum Pharmaceuticals news (Ticker: MIRM), a resource for investors and traders seeking the latest updates and insights on Mirum Pharmaceuticals stock.
Mirum Pharmaceuticals, Inc. (symbol: MIRM) is a biopharmaceutical company headquartered in Foster City, California. Established in 2018, the company focuses on the development and commercialization of innovative therapies aimed at treating debilitating liver diseases. Mirum Pharmaceuticals is dedicated to addressing rare and orphan diseases, making significant strides in this niche sector of the healthcare market.
At the core of Mirum Pharmaceuticals' product pipeline is Maralixibat, an investigational oral drug currently in phase 3 clinical trials. Maralixibat is being studied for its efficacy in treating several severe liver conditions, including Progressive Familial Intrahepatic Cholestasis (PFIC), Alagille Syndrome (ALGS), and Biliary Atresia. This product represents a potential breakthrough in providing therapeutic options for these challenging conditions.
In addition, the company has developed Volixibat, a drug aimed at treating Intrahepatic Cholestasis of Pregnancy (ICP) and Primary Sclerosing Cholangitis (PSC). These ongoing projects highlight Mirum Pharmaceuticals' commitment to advancing the treatment landscape for liver diseases with significant unmet medical needs.
Mirum Pharmaceuticals has achieved notable milestones, such as the approval of Livmarli, an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor. Livmarli is approved for the treatment of cholestatic pruritus in patients with Alagille Syndrome (ALGS), providing much-needed relief for those affected by this condition.
The company stands out for its strategic approach to identifying, acquiring, and developing novel therapies. It has established partnerships and collaborations to bolster its research endeavors and expand its reach in the biopharmaceutical industry. With a robust pipeline and a clear focus on debilitating liver diseases, Mirum Pharmaceuticals continues to make significant progress in its mission to improve patient outcomes and quality of life.
For the latest news and updates about Mirum Pharmaceuticals, including recent achievements, ongoing projects, and financial performance, investors and stakeholders can rely on resources like StockTitan for comprehensive and timely information.
Stay informed about Mirum Pharmaceuticals, Inc. and its groundbreaking work in the biopharmaceutical sector, and keep track of the latest developments and stock performance on StockTitan.
Mirum Pharmaceuticals (Nasdaq: MIRM) presents data at the International Liver Congress™ and the 54th Annual ESPGHAN Meeting. Eight abstracts are accepted, including three oral presentations, with notable research on maralixibat for Alagille syndrome. This data includes predictors of event-free survival and is nominated for the prestigious Alex Mowat Prize. Additionally, Mirum will host scientific symposia at both events, enhancing its position in the treatment of rare liver diseases.
On June 10, 2022, Mirum Pharmaceuticals granted inducement awards under its 2020 Inducement Plan to eight new employees. These awards consist of non-qualified stock options for 43,550 shares and 21,800 restricted stock units (RSUs). The stock options have an exercise price of $21.36 and will vest over four years, while RSUs will vest over three years. The awards comply with Nasdaq Listing Rule 5635(c)(4) and are aimed at incentivizing the new hires to drive growth in Mirum's rare disease treatments.
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) announced the appointment of Saira Ramasastry to its board of directors and audit committee. Ramasastry brings over 20 years of financial leadership, including her experience at Merrill Lynch & Company. CEO Chris Peetz emphasized her strategic experience as crucial for expanding the company’s reach and enhancing its rare disease pipeline. Mirum develops therapies like LIVMARLI® for liver diseases and has ongoing clinical trials for innovative treatments, showing commitment to advancing care for patients.
Mirum Pharmaceuticals has acquired Satiogen Pharmaceuticals, consolidating its licensing obligations for LIVMARLI® and volixibat. This strategic move is anticipated to improve cash flow and reduce royalty payments to high single digits. The total transaction value includes 841,792 shares of common stock and approximately
Mirum Pharmaceuticals (NASDAQ: MIRM) has announced its participation in key virtual investor conferences. The H.C. Wainwright Global Investment Conference is set for May 24, 2022, with a fireside chat starting at 8:30 a.m. ET. Following this, Mirum will present at the Jefferies Healthcare Conference on June 9, 2022, from 9:00-9:30 a.m. ET. The company focuses on treatments for rare liver diseases, with its approved drug LIVMARLI for Alagille syndrome and investigational treatments for various liver diseases.
Mirum Pharmaceuticals, Inc. (MIRM) has granted inducement awards to 18 new employees, comprising 178,000 non-qualified stock options and 52,677 restricted stock units (RSUs) as of May 10, 2022. The stock options have an exercise price of $22.55, corresponding to Mirum's closing price on that date, and will vest over four years. The RSUs will vest over three years. These awards are part of Mirum's 2020 Inducement Plan and adhere to Nasdaq Listing Rule 5635(c)(4). Mirum focuses on rare diseases and is advancing its clinical pipeline for liver diseases.
Mirum Pharmaceuticals reported a total revenue of $12.9 million for Q1 2022, with net product revenue from LIVMARLI® at $10.9 million. This marks significant growth compared to the previous year's figures. Operating expenses decreased to $45.6 million from $47.6 million in Q1 2021. Despite a net loss of $36.6 million (or $1.17 per share), it was an improvement from last year’s loss of $50.5 million. The company anticipates key clinical trial data and regulatory approvals in late 2022, enhancing prospects for future revenue growth.
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) will report its first quarter financial results on May 5, 2022.
A conference call will be held at 8:30 a.m. ET to discuss the company's progress and priorities for 2022. Investors can join via U.S. toll-free dial-in 844-200-6205 or access the call via webcast. Mirum focuses on rare diseases, with its approved medication LIVMARLI® for cholestatic pruritus in Alagille syndrome. The company is also evaluating investigational treatments for various liver diseases and has submitted a Marketing Authorization Application to the European Medicines Agency.
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) announced on April 8, 2022, that its Compensation Committee granted inducement awards of stock options and restricted stock units to five new employees. The awards comprise 25,500 stock options priced at $27.46 each and 12,650 RSUs. The options will vest over four years, while the RSUs will vest over three years. Mirum focuses on developing treatments for rare diseases, with its marketed drug LIVMARLI® approved for cholestatic pruritus in Alagille syndrome patients. The company also has ongoing clinical trials for additional treatments.
On March 10, 2022, Mirum Pharmaceuticals (NASDAQ: MIRM) granted inducement awards to two new employees, consisting of non-qualified stock options for 16,350 shares and 8,150 restricted stock units (RSUs). The stock options have an exercise price of $21.91, equivalent to the company's closing price on the grant date, and will vest over four years. The RSUs will vest over three years. These grants are part of Mirum's 2020 Inducement Plan and comply with Nasdaq regulations.
FAQ
What is the current stock price of Mirum Pharmaceuticals (MIRM)?
What is the market cap of Mirum Pharmaceuticals (MIRM)?
What is the focus of Mirum Pharmaceuticals, Inc.?
What is Maralixibat used for?
Where is Mirum Pharmaceuticals headquartered?
What is Livmarli?
When was Mirum Pharmaceuticals founded?
What is Volixibat being developed for?
What are the recent achievements of Mirum Pharmaceuticals?
How does Mirum Pharmaceuticals contribute to the biopharmaceutical industry?
How can I get the latest updates on Mirum Pharmaceuticals?
What products are in Mirum Pharmaceuticals' pipeline?
